The Evolving Field of Intrahepatic Cholangiocarcinoma

References

• Blechacz B , GoresGJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology48(1), 308–321 (2008).
   PubMed Web of Science ®Google Scholar
• Bragazzi MC , CardinaleV, CarpinoGet al. Cholangiocarcinoma: epidemiology and risk factors. Transl. Gastrointest. Cancer1(1), 21–32 (2012).
   Google Scholar
• Bridgewater J , GallePR, KhanSAet al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol.60(6), 1268–1289 (2014).
   PubMed Web of Science ®Google Scholar
• Khan SA , EmadossadatyS, LadepNGet al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J. Hepatol. 56(4), 848–854 (2012).
   PubMed Web of Science ®Google Scholar
• Yang JD , KimB, SandersonSOet al. Biliary tract cancers in Olmsted County, Minnesota, 1976–2008. Am. J. Gastroenterol.107(8), 1256–1262 (2012).
   PubMed Web of Science ®Google Scholar
• Welzel TM , GraubardBI, El-SeragHBet al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin. Gastroenterol. Hepatol.5(10), 1221–1228 (2007).
   PubMed Web of Science ®Google Scholar
• Fan B , MalatoY, CalvisiDFet al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest.122(8), 2911–2915 (2012).
   PubMed Web of Science ®Google Scholar
• Palmer WC , PatelT. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J. Hepatol.57(1), 69–76 (2012).
   PubMed Web of Science ®Google Scholar
• Sia D , HoshidaY, VillanuevaAet al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology144(4), 829–840 (2013).
   PubMed Web of Science ®Google Scholar
• Andersen JB , SpeeB, BlechaczBRet al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology142(4), 1021–1031 (2012).
   PubMed Web of Science ®Google Scholar
• Patel AH , HarnoisDM, KleeGG, LaRussoNF, GoresGJ. The utility of CA 19–19 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol.95(1), 204–207 (2000).
   PubMed Web of Science ®Google Scholar
• Uenish T , YamazakiO, TanakaHet al. Serum cytokeratin 19 fragment (CYFRA21–1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol.15(2), 583–589 (2008).
   PubMed Web of Science ®Google Scholar
• Hamrick-Turner J , AbbittPL, RosPR. Intrahepatic cholangiocarcinoma: MR appearance. AJR Am. J. Roentgenol.158(1), 77–79 (1992).
   PubMed Web of Science ®Google Scholar
• Anderson CD , RiceMH, PinsonCW, ChapmanWC, ChariRS, DelbekeD. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg.8(1), 90–97 (2004).
   PubMed Web of Science ®Google Scholar
• Edge SB , ComptonCC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol.17(6), 1471–1474 (2010).
   PubMed Web of Science ®Google Scholar
• Nathan H , AloiaTA, VautheyJNet al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann. Surg. Oncol.16(1), 14–22 (2009).
   PubMed Web of Science ®Google Scholar
• Farges O , FuksD, Le TreutYPet al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer117(10), 2170–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Tan JC , CoburnNG, BaxterNN, KissA, LawCH. Surgical management of intrahepatic cholangiocarcinoma – a population-based study. Ann. Surg. Oncol.15(2), 600–608 (2008).
   PubMed Web of Science ®Google Scholar
• Weber SM , JarnaginWR, KlimstraD, DeMatteoRP, FongY, BlumgartLH. Intrahepatic cholangiocarcinoma: resectability, recurrence patter, and outcomes. J. Am. Coll. Surg.193(4), 384–391 (2001).
   PubMed Web of Science ®Google Scholar
• de Jong MC , NathanH, SotiropoulosGCet al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J. Clin. Oncol.29(23), 3140–3145 (2011).
   PubMed Web of Science ®Google Scholar
• Valle JW , WasanH, JohnsonPet al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomized Phase II study – The UK ABC-01 Study. Br. J. Cancer101(4), 621–627 (2009).
   PubMed Web of Science ®Google Scholar
• Chen YX , ZengZC, TangZYet al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer10, 492 (2010).
   PubMed Web of Science ®Google Scholar
• Hyder O , MarshJW, SalemRet al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann. Surg. Oncol.20(12), 3779–3786 (2013).
   PubMed Web of Science ®Google Scholar
• Sapisochin G , FidelmanN, RobertsJP, YaoFY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl.17(8), 934–942 (2011).
   PubMed Web of Science ®Google Scholar
• Wolf RA , RoysEC, MerionRM. Trends in organ donation and transplantation in the United States, 1999–2008. Am. J. Transplant.10(4 Pt 2), 961–972 (2010).
   PubMed Web of Science ®Google Scholar
• Dodson RM , WeissMJ, CosgroveDet al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J. Am. Coll. Surg.217(4), 736–750 (2013).
   PubMed Web of Science ®Google Scholar
• Park SY , KimJH, YoonHJ, LeeIS, YoonHK, KimKP. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin. Radiol.66(4), 322–328 (2011).
   PubMed Web of Science ®Google Scholar
• Kim JH , WonHJ, ShinYM, KimKA, KimPN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am. J. Roentgenol.196(2), W205–W209 (2011).
   PubMed Web of Science ®Google Scholar
• Glimelius B , HoffmanK, SjodenPOet al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol.7(6), 593–600 (1996).
   PubMed Web of Science ®Google Scholar
• Malka D , CerveraP, FoulonSet al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomized, open-label, non-comparative Phase 2 trial. Lancet Oncol.15(8), 819–828 (2014).
   PubMed Web of Science ®Google Scholar